###begin article-title 0
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 26 30 26 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209</sup>
###xml 34 39 <span type="species:ncbi:9606">Human</span>
Mutational Profile of GNAQQ209 in Human Tumors
###end article-title 0
###begin p 1
Conceived and designed the experiments: SL AB. Performed the experiments: SL. Analyzed the data: SL AB. Contributed reagents/materials/analysis tools: SL LF FB FB SM VC AS MR MK MF AM AB. Wrote the paper: SL AB. Critical comments: FB AM.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 127 131 123 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 275 279 271 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
Frequent somatic mutations have recently been identified in the ras-like domain of the heterotrimeric G protein alpha-subunit (GNAQ) in blue naevi 83%, malignant blue naevi (50%) and ocular melanoma of the uvea (46%). The mutations exclusively affect codon 209 and result in GNAQ constitutive activation which, in turn, acts as a dominant oncogene.
###end p 3
###begin title 4
Methodology
###end title 4
###begin p 5
###xml 112 116 112 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
To assess if the mutations are present in other tumor types we performed a systematic mutational profile of the GNAQ exon 5 in a panel of 922 neoplasms, including glioblastoma, gastrointestinal stromal tumors (GIST), acute myeloid leukemia (AML), blue naevi, skin melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas.
###end p 5
###begin title 6
Principal Findings
###end title 6
###begin p 7
###xml 179 183 179 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
We detected the previously reported mutations in 6/13 (46%) blue naevi. Changes affecting Q209 were not found in any of the other tumors. Our data indicate that the occurrence of GNAQ mutations display a unique pattern being present in a subset of melanocytic tumors but not in malignancies of glial, epithelial and stromal origin analyzed in this study.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 127 138 127 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">H, N, K-RAS</italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 182 185 182 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Dunn1">[1]</xref>
###xml 169 174 <span type="species:ncbi:9606">human</span>
Activation of the MAPK signaling pathway plays an important role in tumorigenesis. Multiple components of this pathway such as H, N, K-RAS and BRAF are often mutated in human cancer [1].
###end p 9
###begin p 10
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NRAS</italic>
###xml 121 124 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Saldanha1">[2]</xref>
###xml 228 232 224 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 311 314 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 318 322 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 329 332 325 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 394 398 390 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 551 554 547 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 586 590 582 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 622 625 618 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 662 665 658 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 710 713 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 812 815 808 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 422 427 <span type="species:ncbi:9606">human</span>
Most melanocytic neoplasms show oncogenic mutations in components of the MAPKinase cascade, particularly in BRAF and NRAS[2]. A recent study has reported frequent somatic mutations in the heterotrimeric G protein alpha-subunit (GNAQ) in a subset of melanocytic neoplasms which do not present alterations in the RAS or BRAF genes [3]. Genetic, biochemical and biological analysis has shown that GNAQ behaves as a bona fide human oncogene. The reported mutations occur exclusively in codon 209 in the ras-like domain and lead to constitutive activation [3]. The glutamine at codon 209 of GNAQ corresponding to residue 61 of RAS and is essential for GTP hydrolysis [3]. It has been previously shown that in other RAS family members, mutations at this site cause loss of GTPase activity with constitutive activation [3].
###end p 10
###begin p 11
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 547 550 537 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Hubbard1">[4]</xref>
###xml 788 825 767 796 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Gq&#945; (GNAQ), G11&#945; (GNA11), G14</italic>
###xml 831 838 798 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(GNA14)</italic>
###xml 843 846 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">G15</italic>
###xml 852 859 815 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(GNA15)</italic>
###xml 1004 1007 959 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Hubbard1">[4]</xref>
###xml 1139 1146 1078 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t001">Table 1</xref>
###xml 1155 1159 1094 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1164 1169 1103 1108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA11</italic>
###xml 1284 1290 1223 1229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA 15</italic>
###xml 1424 1427 1363 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Shin1">[5]</xref>
###xml 1429 1435 1368 1374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA 14</italic>
###xml 1517 1520 1456 1459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Hubbard1">[4]</xref>
###xml 1540 1545 1479 1484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA11</italic>
###xml 1588 1592 1527 1531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1628 1632 1567 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1855 1859 1794 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1927 1934 1866 1873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
###xml 2013 2018 1952 1957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA11</italic>
###xml 1031 1036 <span type="species:ncbi:9606">human</span>
###xml 1885 1890 <span type="species:ncbi:9606">human</span>
GNAQ encodes for alpha subunit of q class of heterotrimeric GTP binding protein (Gq) that mediates signals between G-protein-coupled receptors (GPCRs) and stimulates all four isoforms of beta phospholipase C (PLCbeta) that catalyzes the hydrolysis of phosphatidylinositol biphosphate (PIP2). Nearly 40% of GPCRs rely upon Gqalpha family members to stimulate inositol lipid signalling. These include more then 50 subtypes of receptor responsive to a range of hormone, neurotransmitters, neuropeptides, chemokines, autocrine and paracrine molecules [4]. The Gq family members, Gq, G11, G14, and G15/16, like all heterotrimeric G proteins, are composed of three subunits, Galpha, Gbeta and Ggamma, that cycle between inactive and active signalling states in response to guanine nucleotides. Gqalpha (GNAQ), G11alpha (GNA11), G14alpha (GNA14) and G15alpha (GNA15) each have very different tissue and cell expression patterns. Gqalpha and G11alpha mRNA and protein are ubiquitously distributed across tissues [4]. Compared with Gqalpha human, G11alpha, G14alpha, and G15alpha share 90%, 80%, and 57% amino acid sequence identity, respectively (Table 1). While GNAQ and GNA11 are ubiquitously expressed, other members of the family show a very restricted pattern of expression. For example GNA 15 is confined to tissues rich in cell types of hematopoietic origin and are enriched in cells in the earlier stages of differentiation [5]. GNA 14 has been demonstrated to be expressed mainly in kidney, liver, lung and pancreas [4]. Of note exon 5 of GNA11 contains an equivalent residue to Q209 of GNAQ. We hypothesized that mutations in GNAQ may also be present in tumor types from non melanocytic origin where they could represent alternative route to MAPKinase activation. To assess this hypothesis, we performed a systematic mutational profile of exon 5 of the GNAQ gene in a large panel of human tumors from different tissue types (Table 2). In light of its ubiquitous expression we also performed the analysis of the GNA11 gene (exon 5) in the same tumor set.
###end p 11
###begin title 12
###xml 72 77 <span type="species:ncbi:9606">human</span>
Sequence homology (at the protein level) and expression distribution in human tissues among Gq family genes.
###end title 12
###begin title 13
Number of samples analyzed for each histological type and the number of mutations identified.
###end title 13
###begin p 14
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(AML</bold>
###xml 30 34 30 34 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GIST</bold>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 168 172 168 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209</sup>
(AML: acute myeloid leukemia, GIST: Gastrointestinal Stromal Tumors; In addition, p-values of the Fisher's exact test, used to determine the tissue specificity for GNAQQ209 mutations in blue naevi, are listed.)
###end p 14
###begin title 15
Materials and Methods
###end title 15
###begin title 16
Tumor sample and Ethics Statement
###end title 16
###begin p 17
DNA of blue naevi, breast, lung, ovarian and thyroid (papillary and follicular isotopes carcinoma) cancer samples was obtained from the Clinical Research Center, Center of Excellence on Aging at the University-Foundation (Chieti, Italy). Samples were collected according to the ethical requirements and regulations of the review board of the Clinical Research Center, University-Foundation (Chieti, Italy).
###end p 17
###begin p 18
###xml 1808 1815 1808 1815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
###xml 1297 1305 <span type="species:ncbi:9606">patients</span>
###xml 1523 1530 <span type="species:ncbi:9606">patient</span>
DNA of melanoma, colorectal cancer and GIST samples was obtained from the Department of Experimental Oncology at the Institute National Tumori (Milan, Italy). Samples were collected according to the ethical requirements and regulations of the review board of the Istituto Nationale dei Tumori (Milan, Italy). DNA of pancreatic adenocarcinoma (PDAC) was obtained from the Department of Pathology, Section of Anatomic Pathology at the University of Verona (Verona, Italy). Samples were collected according to the ethical requirements and regulations of the review board of the University of Verona (Verona, Italy). Additional DNA samples of thyroid carcinomas (medullary histotype), were obtained from the Department of Cellular Biology and Molecular Pathology at the University of Naples (Naples, Italy). Samples were collected according to the ethical requirements and regulations of the review board of the University of Naples (Naples, Italy). DNA of bladder cancer samples was obtained from the Section of Experimental Oncology at the Leeds Institute for Molecular Medicine (Leeds, United Kingdom). Samples were collected according to the ethical requirements and regulations of the review board Institute for Molecular Medicine (Leeds, United Kingdom). Brain cancer samples were obtained from patients undergoing brain tumor surgery in the Academic Medical Center (Amsterdam, The Netherlands). Consent for removal of the tissue and its storage in the tumor bank for research purposes was obtained and documented in the patient's medical chart. Individual consent for this specific project was waivered by the Academic Medical Center (Amsterdam, The Netherlands) ethics committee because the research was performed on 'waste' material, stored in a coded fashion. The entire tumor database is described in Table 2.
###end p 18
###begin title 19
Isolation of Genomic DNA and mutational analysis
###end title 19
###begin p 20
###xml 49 52 49 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Balakrishnan1">[6]</xref>
###xml 217 240 217 240 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GTAAAACGACGGCCAGT-3&#8242;</named-content>
###xml 289 296 289 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t003">table 3</xref>
Genomic DNA was isolated as previously described [6]. PCR primers were designed using Primer 3 (), and synthesized by Invitrogen/Life Technologies, Inc. (Paisley, England). A universal sequencing primer M13 forward, (5'-GTAAAACGACGGCCAGT-3') was appended to the 5' end used to sequencing (table 3). PCR products size ranged from 180 to 280 bps.
###end p 20
###begin title 21
PCR primers used for the mutational profiling.
###end title 21
###begin p 22
PCRs were performed in 10-uL reaction volumes in 96-well format containing 0.25 mmol/L deoxynucleotide triphosphates, 1 umol/L each of the forward and reverse primers, 6% DMSO, 1xPCR buffer, 1 ng/uL DNA, and 0.05 unit/uL AmpliTaq Gold DNA polymerase (Applied Byosystems, Foster City, CA) A touchdown PCR program was used for PCR amplification (Peltier Thermocycler, PTC-200, MJ Research, Bio-Rad Laboratories, Inc., Italy). PCR products were purified using AMPure (Agencourt Bioscience Corp., Beckman Coulter S.p.A, Milan, Italy). Cycle sequencing was carried out using BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster City, CA) with an initial denaturation at 97degreesC for 3 min, followed by 28 cycles of 97degreesC for 10 s, 50degreesC for 20 s, and 60degreesC for 2 min. Sequencing products were purified using CleanSeq (Agencourt Bioscience, Beckman Coulter) and analyzed on a 3730 DNA Analyzer, ABI capillary electrophoresis system (Applied Biosystems). Sequence traces were analyzed using the Mutation Surveyor software package (SoftGenetics, State College, PA). Only amplicons meeting quality criteria were analyzed: tumor samples had Phred quality scores of >/=20.
###end p 22
###begin p 23
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
To assess whether these results were statistically significant we performed the Fisher's exact test to determine the tissue specificity for GNAQ mutation in blue naevi tumors as compared to the other tumor types.
###end p 23
###begin title 24
Results and Discussion
###end title 24
###begin p 25
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA11</italic>
###xml 258 265 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
###xml 454 457 454 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Balakrishnan1">[6]</xref>
###xml 459 462 459 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Bleeker1">[7]</xref>
###xml 464 467 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Bleeker2">[8]</xref>
###xml 666 670 666 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 707 715 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006833-g001">Figure 1</xref>
###xml 720 727 720 727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
###xml 760 763 760 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 794 798 794 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 860 867 860 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
###xml 922 927 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNA11</italic>
We sequenced exon 5 of the GNAQ and GNA11 genes in in a panel of 922 tumors, including glioblastoma, gastrointestinal stromal tumors, acute myeloid leukemia, blue naevi, melanoma, bladder, breast, colorectal, lung, ovarian, pancreas, and thyroid carcinomas (Table 2). The samples included in the analysis have been previously used for mutational profiling of cancer genes and we have shown that common mutations can be identified in this tumors database [6], [7], [8]. A total of 1844 PCR products, spanning 423 kb of tumor genomic DNA, were generated and subjected to direct sequencing. Sequences analysis identified the presence of the Q209L (c.A627T) mutation in GNAQ in 6/13 (46%) of blue naevi tumors (Figure 1 and Table 2), thus confirming previous data [3]. Importantly, no mutations of GNAQ exon 5 were found in any tumor types, other than blue naevi (Table 2). Similarly, we did not detect mutations in exon 5 of GNA11.
###end p 25
###begin title 26
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
Example of one of the GNAQ mutations identified in blue naevi.
###end title 26
###begin p 27
The arrow indicates the location of the missense change p.Q209L (c.A627T).
###end p 27
###begin p 28
###xml 140 144 140 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 212 219 212 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006833-t002">Table 2</xref>
To assess whether these results were statistically significant we performed the Fisher's exact test to determine the tissue specificity for GNAQ mutation in blue naevi tumor as compared to the other tumor types (Table 2).
###end p 28
###begin p 29
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 143 147 143 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209</sup>
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ<sup>Q209</sup></italic>
###xml 161 166 <span type="species:ncbi:9606">human</span>
Our data confirm that GNAQ is a pivotal cancer gene in blue naevi while at the same time unveils a striking tissue-specific pattern of the GNAQQ209 mutations in human cancer.
###end p 29
###begin p 30
###xml 328 331 328 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 687 690 687 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 721 724 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 729 733 729 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 822 826 822 826 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209</sup>
###xml 818 826 818 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ<sup>Q209</sup></italic>
###xml 948 952 948 952 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1126 1129 1126 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Shin1">[5]</xref>
###xml 1178 1182 1178 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1430 1431 1410 1411 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1471 1472 1451 1452 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 1619 1622 1595 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-VanRaamsdonk1">[3]</xref>
###xml 1646 1650 1622 1626 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1683 1686 1659 1662 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 1700 1703 1676 1679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RAS</italic>
###xml 1751 1754 1727 1730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PKC</italic>
###xml 1778 1781 1754 1757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006833-Radhika1">[9]</xref>
###xml 1922 1926 1898 1902 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 1976 1980 1952 1956 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Q209</sup>
###xml 1972 1980 1948 1956 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ<sup>Q209</sup></italic>
###xml 2046 2050 2022 2026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GNAQ</italic>
###xml 178 188 <span type="species:ncbi:203779">large blue</span>
Blue naevi arise from intradermal melanocytic proliferations, which can be congenital or acquired, and present in diverse ways ranging from discrete bluish moles (blue naevi) to large blue-grey patches affecting the conjunctiva and periorbital skin (naevus of Ota), shoulders (naevus of Ito) and the lower back (Mongolian spot) [3]. Uveal melanomas are thought to originate from melanocytes within the choroidal plexus of the eye and are distinct from cutaneous melanoma by characteristic cytogenetic alterations. Of note, a potential connection between intradermal melanocytic neoplasms and uveal melanoma is suggested by the fact that naevus of Ota is a risk factor for uveal melanoma [3]. Oncogenic alterations in the RAS and BRAF genes are known to frequently affect cutaneous melanoma. Until the discovery of the GNAQQ209 mutations there were no oncogenes altered at high frequency in uveal melanomas and blue naevi. The tissue-specificity of GNAQ mutations may be linked to its involvement in endothelin signaling, which is important for development of melanocytes and also is required for the migration of melanoblasts [5]. The canonical downstream signaling pathways of GNAQ are the beta-isoforms of phospholipase C (PLC-beta). Gqalpha, G11alpha, bind and stimulate PLC-beta enzymes to initiate inositol lipid signalling. PLC-beta enzymes catalyze the hydrolysis of the phospholipid phosphatidylinositol bisphosphate, (PIP2), to release inositol trisphosphate (IP3) and diacylglycerol (DAG). These second messengers propagate and amplify the Galpha-mediated signal trough stimulation of protein kinase C (PKC). [3] One hypothesis is that GNAQ regulates cell growth through a RAS dependent or RAS- independent signaling mechanism involving the PKC-dependent ERK pathway. [9]. Functional assays are now required to assess this possibility and to understand in details the oncogenic signaling mechanisms regulated by GNAQ mutant alleles. Targeting either the mutated GNAQQ209 protein or the oncogenic signaling pathway controlled by mutated GNAQ may open up new therapeutic strategies for melanocytic tumors.
###end p 30
###begin p 31
The authors thank Dr F. Di Nicolantonio for critical reading of the manuscript, Dr. S. Leenstra, Dr. T Hulsebos, and Professor Troost for making glioblastoma tumor samples available from the Brain Tumor Bank maintained by the Departments of Neurosurgery, Neuropathology, and Neurogenetics, Academic Medical Center, Amsterdam. Dr Aniello Cerrato and Dr Massimo Santoro for providing the DNA samples of thyroid carcinomas (medullary histotype).
###end p 31
###begin title 32
References
###end title 32
###begin article-title 33
The Ras-MAPK signal transduction pathway, cancer and chromatin remodelling.
###end article-title 33
###begin article-title 34
High BRAF mutation frequency does not characterize all melanocytic tumor types.
###end article-title 34
###begin article-title 35
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi.
###end article-title 35
###begin article-title 36
Cell signalling diversity of the Gqa family of heterotrimeric G proteins.
###end article-title 36
###begin article-title 37
The temporal requirement for endothelin receptor-B signalling during neural crest development.
###end article-title 37
###begin article-title 38
Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma.
###end article-title 38
###begin article-title 39
###xml 14 19 <span type="species:ncbi:9606">human</span>
AKT1(E17K) in human solid tumours.
###end article-title 39
###begin article-title 40
IDH1 Mutations at Residue p.R132 (IDH1R132) OccurFrequently in High-Grade Gliomas But Not in Other Solid Tumors.
###end article-title 40
###begin article-title 41
Transforming G proteins.
###end article-title 41
###begin p 42
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 42
###begin p 43
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by grants from Italian Association for Cancer Research (AIRC), Italian Ministry of Health, Regione Piemonte, Italian Ministry of University and Research, CRT Progetto Alfieri, Fondazione Monte dei Paschi di Siena, Association for International Cancer Research (AICR-UK) , EU FP6 contract n 037297 (MCSC), EU FP7 Marie Curie, contract n 218071 (Cancer-Gene). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 43

